competition in Brazil’s pharma and healthcare sector is becoming increasingly intense. The deceleration of the domestic drug market has propelled the pharmaceutical companies operating in the country to search for scale and efficiency gains through organic growth, acquisitions and internationalisation of their operations. The opening of the healthcare market to foreign investors in January 2015 also unleashed a consolidation trend, triggered by the entry of both strategic and institutional investors. Given the deficiencies in the provision of quality health services, healthcare will remain the subsector with the highest growth potential in the medium term.

01 EXECUTIVE SUMMARY 

02 SECTOR OUTLOOK 

03 SECTOR IN FOCUS 

04 COMPETITIVE LANDSCAPE 

05 COMPANIES IN FOCUS

06 REGULATORY ENVIRONMENT 

07 PHARMACEUTICALS 

08 HEALTHCARE 

09 RETAIL CHANNELS